Pharma and Biotech Daily: Roche's $1 Billion Deal, Neumora's Setback, and More Updates

Pharma and BioTech Daily

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Roche has recently finalized a new deal in China valued at up to $1 billion for an antibody-drug conjugate. However, Neumora's depression drug trial has unfortunately not yielded successful results. Additionally, Sangamo has experienced a setback by losing a partnership with Pfizer in hemophilia gene therapy. On a more positive note, Axsome has released mixed data from Alzheimer's trials but still plans to move forward with filing for FDA approval.In other recent developments, Merck's PAH drug and BMS' Opdivo injection have received regulatory greenlights. It's important to note that there are currently job opportunities available in various pharmaceutical companies for those looking to make a career move in the industry.Looking ahead to 2024, the neurobiopharma industry has been characterized as a rollercoaster of ups and downs.